Consensus TransCode Therapeutics, Inc.

Equities

RNAZ

US89357L3033

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-09 pm EDT			5-day change	1st Jan Change
1.33 ^USD	+30.39%		+88.12%	-79.82%

Apr. 22	Certain Warrants of TransCode Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-APR-2024.	CI
Apr. 22	Certain Stock Options of TransCode Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-APR-2024.	CI

Evolution of the average Target Price on TransCode Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

fabe65c6a1e071645.sGjQXQ-ajuVnHHzAUaBoO2K0ebavTvtfCqp_kHSUXAo.hCnob0TQ45w0dE-IMtokcy35M_DAG4kHXeUg9BbTLEXZJLIsX6q_qhZwEw~f927e3d9af87467934aafe046b6b4081

Analyst Recommendations on TransCode Therapeutics, Inc.

Wall Street Set to Open Wednesday Trading Higher as Investors Await Fed Decision on Interest Rates	23-09-20	MT
US Futures Rise Modestly Pre-Bell as Investors Await Fed Rate Decision	23-09-20	MT
Traders Stay Cautious Ahead of Fed Rate Decision, Weighing on US Equity Futures	23-02-01	MT
HC Wainwright Adjusts Price Target on TransCode Therapeutics to $6 From $10, Maintains Buy Rating	22-11-15	MT
HC Wainwright Starts TransCode Therapeutics at Buy With $10 Price Target	22-06-07	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.02 USD

Average target price

3 USD

Spread / Average Target

+194.12%

High Price Target

3 USD

Spread / Highest target

+194.12%

Low Price Target

3 USD

Spread / Lowest Target

+194.12%

Consensus detail

Consensus revision (last 18 months)

Analysts covering TransCode Therapeutics, Inc.

HC Wainwright

Quarterly revenue - Rate of surprise

Company calendar